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Purpose: To review and integrate recent advances in identifying the role of inﬂ  ammation in 
the pathogenesis of dry eye conditions and the biological rationale and practical clinical aspects 
of newer, antiinﬂ  ammatory theories.
Methods: A comprehensive literature survey.
Results and conclusion: Keratoconjunctivitis Sicca (KCS) is a multifactorial and complex 
disorder in which ocular surface inﬂ  ammations play a central role. Identiﬁ  cation of speciﬁ  c 
CD4-T-Cell pathways and the recent recognition of targeting of alpha-fodrin suggest a case 
for novel new therapeutic aspects such as anti-CD4 monoclonal antibodies, systemic linoleic 
and gamma-linolenic acids, and omega-6 essential fatty acids. Replacement of tear volume 
with nonpreserved wetting agents and standard typical antiinﬂ  ammatory corticosteroid and/or 
cyclosporine A continues to be central current conventional therapy for KCS.
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Dry eye disease or keratoconjunctivitis sicca (KCS) is a common disorder which 
refers to a spectrum of ocular surface diseases with multiple etiologies.1 KCS is asso-
ciated with symptoms of ocular discomfort such as burning, sense of dryness, foreign 
body sensation, ocular pain, and is sometimes associated with photophobia, blurred 
vision, visual fatigue, and sight-threatening corneal complications in severe cases.2,3 
Epidemiologic studies have stated that more than 6% of the population complains of 
dry eye symptoms, and this ratio increases to 15% over the age of 65.4–6 Most of the 
studies have also found an increasing prevalence with aging and greater prevalence 
among women due to the hormonal status.4,6,7
Pathogenesis of KCS has not been completely clarified. Even though 
KCS has been thought of classically and basically as a condition of tear defi-
ciency, whether caused by decreased lacrimation or excessive evaporation, it 
is a complex disorder. Many clinicopathological entities involving tear film, 
lacrimal glands, eyelids, and a wide spectrum of ocular surface cells, includ-
ing epithelial, inflammatory, immune, and goblet cells may play a role in its 
pathogenesis.2,8
Over the past years, as a result of numerous studies, new concepts of pathogenesis 
have shown that KCS seems to be caused by inﬂ  ammation mediated by T-cell lympho-
cytes.9–11 This ﬁ  nding has also been augmented by the studies investigating the role of 
antiinﬂ  ammatory therapies. For instance, the treatment of KCS gained a new dimension 
with the approval of topical 0.05% cyclosporine A (Restasis) (Allergan, Inc., package 
insert for Restasis) by the US Food and Drug Administration. Consequently, because 
of the increasing importance of the role of inﬂ  ammation and the use of cyclosporine 
eye drops, the goal of this review article is to provide the readers with an overview of Clinical Ophthalmology 2009:3 58
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the role of inﬂ  ammation and also to discuss antiinﬂ  ammatory 
therapies such as topical cyclosporine in KCS.
Inﬂ  ammaton in dry eye
Lacrimal gland inﬂ  ammation
The lacrimal gland that secretes proteins, electrolytes and 
water is the main contributor to the aqueous layer of the tear 
ﬁ  lm. With these properties, it helps to nourish and protect the 
ocular surface. Lacrimal gland secretion is primarily under 
neural control, which is achieved through a neural reﬂ  ex arc 
functioning as an integrated or “functional unit”.8,12 Stimuli 
to the ocular surface activate afferent sensory nerves in the 
cornea and conjunctiva. This stimulus then goes to the central 
nervous system in the area of pons via the ophthalmic branch 
of the trigeminal nerve. In the end, it activates efferent nerves 
consisting of parasympathetic ﬁ  bers which travel in the facial 
nerve and sympathetic ﬁ  bers emerging from the paraspinal 
sympathetic chain to stimulate secretion.8,12 As mentioned 
above, it has been suggested that KCS is an inﬂ  ammatory 
disorder that affects both the ocular surface and the lacrimal 
gland. For instance, in some clinical disorders such as Sjögren’s 
syndrome (SS), graft versus host disease, sarcoidosis and as a 
result of aging the lacrimal gland may become an important 
target of the immune system and show signs of inﬂ  ammation.12 
The presence of focal lymphocytic inﬁ  ltrates and increased 
production of proinﬂ  ammatory cytokines are the characteristic 
ﬁ  ndings of lacrimal gland inﬂ  ammation.12
Sjögren’s syndrome, is most likely to affect females, 
and overall is a systemic and multifactorial inﬂ  ammatory 
disease affecting primarily the lacrimal and salivary glands, 
resulting in dry mouth and dry eyes.12,13 It may be seen as 
a primary disease or can be associated with other autoim-
mune diseases such as rheumatoid arthritis, systemic lupus 
erythematosus, or systemic sclerosis.13 The diagnosis of SS 
is often difﬁ  cult, especially in the early stages of the disease. 
At this point, circulating antibodies presumably produced by 
B cells are a characteristic hallmark of SS and may be useful 
for the diagnosis.14 Apart from the most commonly detected 
auto-antibodies such as Ro/SSA and La/SSB,15 which are 
directed against ribonucleoproteins and are included in the 
European-American Diagnostic Criteria for primary SS, 
there are also other autoantibodies against α-fodrin and M3 
muscarinic receptors.16–18 The presence of autoantibodies 
Ro/SSA and La/SSB was found to be generally associated 
with a longer disease duration, increased frequency of non-
exocrine manifestations and a higher intensity of lymphocytic 
inﬁ  ltrates invading the minor salivary glands.19 Recent case 
reports and some research have shown that autoantibodies 
against α-fodrin may be used in the diagnosis and may 
also be considered as an activation marker of SS with dry 
eye.20–22 Interestingly, it has been determined that the posi-
tive anti-α-fodrin antibody might support the diagnosis of 
SS even with negative results of anti-Ro/SSA and anti-
La/SSB.22 In addition to the presence of these antibodies 
in serum, anti-Ro/SSA and anti-La/SSB antibodies may be 
present in the tear ﬂ  uid of some patients with SS, and their 
presence in serum or tear ﬂ  uid may be a clinical marker for 
the severity of KCS.23 Circulating autoantibodies against 
muscarinic acetylcholine receptors (mAChRs) have also 
been investigated, and it has been emphasized that it could 
be a new marker to differentiate SS dry eye from non-SS 
dry eye.24 In another study, it has been stressed that besides 
these antibodies’ contribution to sicca symptoms, autoan-
tibodies acting as antagonists at M3-muscarinic receptors 
might explain associated features of autonomic dysfunction 
in some SS patients.25
Apart from autoantibodies, pro-inﬂ  ammatory cytokines 
such as interleukin-1β (IL-1β) seem to be very crucial in the 
pathophysiological understanding of KCS.26 For instance, 
IL-1β may cause a marked increase in nitric oxide (NO) 
production via induction of iNOS in lacrimal gland epithe-
lial cells, and hence overproduction of NO may be a factor 
in lacrimal gland cell death in KCS.26 Moreover, inhibitors 
of iNOS or IL-1 receptor may be beneﬁ  cial for controlling 
lacrimal gland inﬂ  ammation26 and may help us to control the 
dry eye symptoms in SS patients. In an animal model inves-
tigating the relationship between interleukin-1β-induced 
NO production and sex-hormones, it has been reported 
that androgens and estrogens can downregulate cytokine-
mediated responses in lacrimal gland acinar cells that are 
important for the maintenance of ocular surface protection 
and thereby may play an important role in regulating inﬂ  am-
matory responses in the eye.27 This ﬁ  nding may help us to 
explain the increasing prevalence of dry eye symptoms in 
postmenopausal women. In another study supporting the 
possible contribution of above-mentioned iNOS pathway 
both to the pathogenesis and to the treatment of KCS, the 
role of c-Jun NH2-terminal kinase (JNK) in IL-1β-mediated 
inhibition of lacrimal gland secretion and tear production was 
explained, and it was documented that treatment for 7 days 
with SP600125 that is the inhibitor of JNK increased tear 
production in a murine model of SS dry eye.28
Another important disorder based on inflammatory 
etiology and resulting in dry eye symptoms is sarcoidosis 
which is a multisystemic disorder of unknown etiology and 
characterized by the presence of noncaseating granulomas Clinical Ophthalmology 2009:3 59
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in multiple organs such as lungs, spleen, liver, lymph nodes, 
skin, and salivary and lacrimal glands.12,29,30 Because patients 
with sarcoidosis may complain about dry eye and dry mouth 
as occur in SS, it may be very difﬁ  cult to differentiate 
between the two diseases.
The lacrimal gland is not the only effected site for sarcoid-
osis but the orbit, lacrimal sac, eyelid, etc can be involved as 
well.31 It as been documented that tear ﬁ  lm deﬁ  ciencies are 
common in sarcoidosis, even though clinical symptoms are 
present. In the same study, it was emphasized that deﬁ  ciency 
of mucin and lipid layers may also accompany aqueous layer 
deﬁ  ciency.32
In sarcoidosis, it has been thought that exposure to an 
environmental antigen in a genetically susceptible individual 
may trigger an immunologic response in many organs, as 
mentioned above.33 In the pathogenesis of granuloma forma-
tion, a complex interaction is thought to occur between many 
cell types, cytokines, and chemokines.34 The main immuno-
pathologic characteristic of involved organs is the accumula-
tion of activated lymphocytes, predominantly T helper cells, 
expressing the Th1 phenotype and monocytes/macrophages. 
Chemokines are also required for the extravasation of leu-
kocytes to the inﬂ  ammation site. In one study to determine 
which chemokines are augmented in the serum of patients 
with active ocular sarcoidosis, serum levels of CXCL9 and 
CXCL10 were found to be elevated markedly in the patients 
with ocular sarcoidosis and correlated with ocular disease 
activity and angiotensin-converting enzyme (ACE) level.35 In 
another study, increased circulating IL-12 p40, which is one 
of the most important cytokines for promoting Th1 reaction, 
was found to be an important systemic marker for disease 
activity, and it has been emphasized that it may reﬂ  ect the 
increased interaction between IL-12 and its ligand IL-12R 
in sarcoid lesions of involved organs.36 Another important 
ﬁ  nding is the increased levels of proinﬂ  ammatory cytokines 
such as tumor necrosis factor-α (TNFα) in sarcoidosis.37,38 
TNFα exerts its effect by binding to speciﬁ  c cell surface 
receptors such as membrane TNF receptor (mTNFR)-1 and 
mTNFR-2, and can be blocked by soluble TNF receptor 
(sTNFR)-1 and sTNFR-2.39 Because of these properties, in 
the past several years, both TNFα monoclonal antibody and 
soluble TNF receptor have been investigated for the treatment 
of sarcoidosis, and ocular involvement as well. The details of 
treatment strategies for dry eye are explained in the second 
section of this review.
Chronic graft versus host disease (GVHD) is an impor-
tant entity for patients undergoing hematopoietic stem cell 
transplantation because of the hematologic malignancies, 
induced by the reaction of donor T cells to recipient 
histoincompatible antigens.40,41
The importance of GVHD for the ophthalmologist comes 
from its ocular complications. Severe dry eye is one of the 
most frequent ocular complications of GVHD.42 Apart from 
the importance of CD4 and CD8 (+) lymphocytes which were 
found primarily in the periductal areas of the lacrimal glands 
in patients with chronic GVHD, one of the most important 
additional findings is marked fibrosis of the glandular 
interstitium and an increased number of CD34 (+) stromal 
ﬁ  broblasts.43 Proinﬂ  ammatory cytokines also play a critical 
role in the pathogenesis of GVHD similar to those which 
occur in all immunologic events such as SS.44
In most of the studies, the prevalence and/or incidence 
of KCS were found to be higher in older patients.45,46 This 
ﬁ  nding has also motivated many researchers to investigate 
and clarify the underlying pathophysiology of aging on lac-
rimal glands. For instance, in one of these studies, an animal 
model, aiming to investigate the effect of aging on lacrimal 
gland structure, innervation and function using BALB/c 
mice at different ages, it has been concluded that notable 
changes occurring with aging are the increased accumula-
tion of lipofuscin-like inclusions, chronic inﬂ  ammation and 
functional alterations including decreased acetylcholine 
release and protein secretion.47 In addition to these ﬁ  ndings 
such as chronic inﬂ  ammation and mast cell inﬁ  ltration to 
the lacrimal gland occurring with aging, morphological and 
functional changes in acini has also occurred resulting in 
reduction or an inability to synthesize and to secrete protein 
from the glands of aged animals as compared to the glands 
of young rats.48
Ocular surface inﬂ  ammation
In KCS patients, ocular surface inflammation can be 
evaluated as both the cause and the consequence of cell 
damage.49 Whether it is a cause or a consequence, it is 
well known that a dangerous vicious circle occurs between 
ocular inﬂ  ammation and dry eye, and in turn may lead to 
sight-threatening complications. There are numerous fac-
tors that may contribute to the formation of ocular surface 
inﬂ  ammation such as desiccating stress,50 hyperosmolar-
ity,51 proinﬂ  ammatory cytokines released from the lacrimal 
glands,12 and blinking abnormalities.52
The role of inﬂ  ammatory cytokines and matrix metal-
loproteinases (MMPs) in the pathogenesis of dry eye seems 
to be very important for both the easier understanding of 
KCS and for the discovery of new therapeutic agents. IL-1 
is one of the most studied cytokines accompanying KCS. Clinical Ophthalmology 2009:3 60
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For instance, in one study by Solomon and colleagues it was 
documented that an increase in the proinﬂ  ammatory forms 
of IL-1 (IL-1α and mature IL-1β) and a decrease in the bio-
logically inactive precursor IL-1β were found in tear ﬂ  uid 
in dry eye.53 Moreover, the source of the increased levels of 
IL-1 in the tear ﬂ  uid of patients with KCS was thought to 
be the conjunctival epithelium.53 Recently, reactive nitrogen 
species have just been investigated in dry eye and it has been 
suggested that they might be involved in the pathogenesis or 
self-propagation of autoimmune dry eye (SS).54 In the same 
study, IL-1β, IL-6, IL-8, TNFα were also investigated and 
the staining of these cytokines was found to be more in dry 
eyes in contrast to normal eyes.54
The response of cells to extracellular stimuli such as ocu-
lar surface stress including increased tear ﬁ  lm and ultraviolet 
light exposure is mediated in part by a number of intracellular 
kinase and phosphatase enzymes.55,56 Stress-activated protein 
kinases have been identiﬁ  ed for this purpose.56 And it has 
been documented that activation of these stress pathways 
results in transcription of stress related genes, including 
inﬂ  ammatory cytokines such as IL-1 and TNF-α and MMPs, 
mainly MMP-9.56 In another study, mitogen-activated protein 
kinases (MAPKs) were found to stimulate the production of 
inﬂ  ammatory cytokines and MMPs including IL-β, TNF-α, 
and MMP-9.57
As mentioned above, hyperosmolarity is one of the fac-
tors contributing to ocular surface inﬂ  ammation. In one study 
investigating whether exposure of human limbal epithelial 
cells to hyperosmotic stress activates the MAPK pathways 
and induces production of pro-inﬂ  ammatory cytokines, it 
was concluded that hyperosmolarity induces inﬂ  ammation 
in human limbal epithelial cells by increasing expression and 
production of pro-inﬂ  ammatory cytokines and chemokines 
such as IL-1β, TNF-α, and the C-X-C chemokine IL-8, and 
that this process appears to be mediated through activation 
of the c-Jun N-terminal kinases (JNK) and extracellular-
regulated kinase (ERK) MAPK signaling pathways.58 All 
these factors should not only be considered as important 
factors in the pathogenesis of KCS but also they should 
be kept in mind when discussing the treatment strategies. 
For instance, the efﬁ  cacy of corticosteroid and doxycycline 
which are mostly used for treating ocular surface diseases 
may be explained by their ability to suppress JNK and ERK 
signaling activation and inﬂ  ammatory mediator production 
in the limbal epithelium.58,59
One of the most important components of the ocular 
surface is highly glycosylated hydrophilic glycoproteins, 
the mucins, which help a tear ﬁ  lm to be held in place by 
wet-surfaced, stratiﬁ  ed corneal and conjunctival epithelia.60,61 
They are expressed by ocular surface epithelia and vital to 
the maintenance of healthy epithelial surfaces including the 
ocular surface.60,61 Mucins that have been detected in the 
eye including MUC1, MUC2, MUC4, MUC5AC, MUC 7, 
MUC13, MUC15, MUC16, and MUC17 are classiﬁ  ed as 
transmembrane and secretory.1 While conjunctival goblet 
cells secrete the large gel-forming mucin MUC5AC, and lac-
rimal gland epithelia secrete the small soluble mucin MUC7, 
apical cells of the stratiﬁ  ed epithelium of both corneal and 
conjunctival epithelium express at least three membrane-
associated mucins including MUCs 1, 4, and 16.60,61 The 
membrane-associated mucins form the glycocalyx, which 
provides an important continuous barrier across the surface of 
the eye for preventing pathogen penetrance and has signaling 
capabilities that inﬂ  uence epithelial activity.60,61 As explained 
above, because of their importance, alteration of either mucin 
distribution or mucin glycosylation on the surfaces of apical 
epithelial cells are also involved in the pathogenesis of dry 
eye.62 For instance, while MUC5AC expression is reduced in 
SS, glycosylation of MUC16 appears to be altered in non-SS 
dry eye patients.61
Other important factors that might contribute to ocular 
surface inﬂ  ammation and in turn result in dry eye are the 
loss of peptide growth factors (ie, epidermal growth factor) 
and vitamin A which are necessary for cellular prolifera-
tion, migration, normal differentiation, immune modula-
tion, and ocular wound healing.1,63,64 However, further 
investigations are needed to clarify these molecules’ exact 
roles in the pathogenesis of ocular surface inﬂ  ammation 
and also KCS.
Blepharitis, meibomian gland dysfunction, 
and ocular allergy
Because of both anatomic proximity and functional 
interactions between lids and ocular surface, it becomes 
unavoidable not to consider dry eye symptoms in many 
of the cases with associated blepharitis, meibomian gland 
dysfunction, and ocular allergy. There is a mutual cause-
effect relationship between these disorders. For instance, 
while blepharitis and/or meibomian gland dysfunction may 
contribute to KCS by two mechanisms including lipid layer 
alteration in tear ﬁ  lm leading to evaporative dry eye symp-
toms and directly effect ocular surface inﬂ  ammation by pro-
viding antigenic and proinﬂ  ammatory cytokine substances, 
on the other hand, KCS may increase the susceptibility to 
blepharitis due to the decreased tear antimicrobial activity 
and tear clearance.1,65,66Clinical Ophthalmology 2009:3 61
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During practical clinical applications, practitioners may 
sometimes face difﬁ  culties in differentiating ocular allergy 
and KCS due to the number of overlapping symptoms. 
Actually, not only the symptoms are similar, but also there 
are some similarities between these two disorders in respect 
of molecular mechanisms involved in the pathogenesis of 
these disorders. In particular, it has been documented that 
allergic conjunctivitis deteriorates normal tear ﬁ  lm structures 
with inﬂ  ammatory basis and in turn predispose a patient to 
dry eye.67 Moreover, eye rubbing related to ocular allergy 
and severe blepharitis may also disrupt the epithelium and 
induces signiﬁ  cant alteration in the inﬂ  ammatory cell inﬁ  l-
trate of the conjunctiva, and thereby inﬂ  uences the course 
of ocular surface diseases such as KCS by worsening the 
inﬂ  ammation on the ocular surface.68
The association between lacrimal gland dysfunction, 
ocular surface inﬂ  ammation, and KCS is summarized in 
Figure 1.
Antiinﬂ  ammatory therapy 
strategies in dry eye
Antiinﬂ  ammatory therapy and some new novel medications 
have been discussed more comprehensively since numerous 
evidences showing the role of inﬂ  ammation in the pathogene-
sis of KCS were established. As mentioned above, KCS tends 
to be accompanied by underlying inﬂ  ammation; therefore the 
use of antiinﬂ  ammatory medications might prove beneﬁ  cial 
for both the subjective and objective complaints of dry eye. In 
this section of the review, we present up-to date antiinﬂ  am-
matory therapy strategies discussing both well-known and 
newly designed current novel medications.
Topical 0.05% cyclosporine
As a result of numerous research projects investigating 
how to cope with an underlying inﬂ  ammation in cases with 
KCS, a new therapy, cyclosporine (CsA) 0.05% ophthalmic 
emulsion (Restasis) has been approved by the Unite States 
Figure 1 This schematic ﬁ  gure reveals the association of ocular surface inﬂ  ammation, lacrimal gland dysfunction, and keratoconjunctivitis sicca.
Abbreviations: MMP, matrix metalloproteinase; JNK, c-Jun NH2 terminal kinase; MAPKs, mitogen activated protein kinases; ERK, extracellular-signal regulated kinase; IL, 
interleukin; TNF, tumor necrosis factor; CXCL, chemokine ligand.Clinical Ophthalmology 2009:3 62
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Food and Drug Administration to increase tear production 
in moderate to severe cases. In fact, CsA has been used 
as an immune modulating drug to prevent tissue or organ 
rejections after transplantations. Moreover, acquaintanceship 
between CsA and ocular disorders is based on the past. For 
instance, systemic CsA has been used in the treatment of 
various autoimmune diseases with ocular involvement.69 In 
ophthalmology, topically applied CsA was ﬁ  rst used to inhibit 
experimental corneal allograft reaction;70 later it became an 
important agent that can be used in various ocular surface 
inﬂ  ammations.71,72
CsA, which is a fungal derived peptide, has potent 
immunosuppressive properties which prevent the transcrip-
tion of cytokine genes in activated T cells.73 At this point, the 
question is what kind of characteristics makes CsA one of 
the most highly potent immunosuppressive drugs? In order 
to explain this, we have to know its mechanisms. CsA ﬁ  rst 
binds to cyclophilin in a cytoplasm and makes a complex, 
and then inhibits the phosphatase activity of calcineurin 
which is so crucial for nuclear translocation and activation of 
the nuclear factor of activated T cells (NFAT) transcription 
factors.73 In an in vitro study that evaluated the modulatory 
effects of dexamethasone and CsA on the production of 
cytokines and chemokines by human corneal cells in vitro 
following stimulation by the pro-inﬂ  ammatory cytokine after 
IL-1β, CsA was not found to have direct immunosuppressive 
effects on human corneal epithelial cells and human corneal 
ﬁ  broblasts.74 This ﬁ  nding also suggests that topical CsA’s 
clinically observed immunosuppressive effects are mainly 
mediated by the immune cells.74 Moreover, CsA also blocks 
the activation of JNK and p38 signaling pathways during 
T-cell activation.75 Besides these properties, it has also been 
suggested that CsA has the potential to increase tear-ﬂ  uid 
secretion by releasing a neurotransmitter such as substance 
P from sensory nerve endings which interact with the para-
sympathetic nerves.76
Because of its powerful immune modulator effect 
described above, 0.05% CsA ophthalmic emulsion has 
been used widely not only in KCS cases but also in other 
various ocular surface diseases including vernal kerato-
conjunctivitis, atopic keratoconjunctivitis, Thygeson’s 
superficial punctuate keratitis, noninfectious keratitis, 
ligneous conjunctivitis, lichen planus, and superior limbic 
keratoconjunctivitis.77
Prior to the achievements accomplished in the 
pathogenetic of dry eye, the general approach to treating 
dry eye cases was to lubricate the ocular surface by using 
artiﬁ  cial tear drops, ointments, and pomades without treating 
the underlying pathogenetic factor such as inﬂ  ammation. 
However, use of antiinﬂ  ammatory agents is showing a 
gradual increase in the treatment of KCS due to the fact that 
several clinical studies have shown topical CsA to improve 
both objective and subjective sign of KCS.78–81 For instance, 
in one study investigating the effect of 0.05% topical CsA 
on the ocular surface and tear functions in cases with 
chronic GVHD, it was suggested that CsA may improve the 
ocular surface and tear functions by decreasing inﬂ  amma-
tion, increasing goblet cell density and MUC5AC mRNA 
expression.82 In another study comparing the efﬁ  cacy of 
topical CsA, punctual occlusion, and a combination for the 
treatment of dry eye, addressed the ﬁ  nding that these three 
regimens revealed improvement in examination parameters 
but at the same time a combination therapy (punctual occlu-
sion and topical CsA) was found to be superior to plugs alone 
in decreasing artiﬁ  cial tear use at 6 months.83 However, pos-
sible adverse effects of punctual occlusion on lacrimal gland 
functions should not be forgotten. For instance, Yen and 
colleagues concluded that temporary punctual occlusion in 
normal subjects decreases tear production and ocular surface 
sensation because of the damage of ocular surface/lacrimal 
gland interaction.84 Similar findings were documented 
by another study by Pﬂ  ugfelder and colleagues.85 In that 
study, they suggested that punctual occlusion may worsen 
dry eye parameters, and premature occlusion may harm the 
biofeedback loop to the ocular surface enervation.85 In addi-
tion to these ﬁ  ndings, inserting a plug may result in keeping 
inﬂ  ammatory cells, cytokines, chemokines, and MMPs on 
the ocular surface. However, it does not mean that punctual 
plugs should not be used in patients with KCS. In selected 
cases, especially after inﬂ  ammation is under controlled, 
punctual plugs are still important parts of the treatment in 
patients with severe KCS.
Kunert and colleagues also supported the positive effect 
of topical CsA on lymphocyte activation within the con-
junctiva of Sjögren’s and non-Sjögren’s dry eye patients.10 
According to that study, a statistically signiﬁ  cant decrease 
in the number of cells expressing the lymphocyte activation 
markers CD11a and HLA DR was found in the case group 
who took topical 0.05% CsA.10 Another similar study has 
demonstrated a signiﬁ  cant decrease in IL-6 in the conjunc-
tival epithelium of SS patients treated with 0.05% CsA for 
6 months.86 In the same study, it was also concluded that IL-6 
was not different from the baseline at 3 months.86 Based on 
this last ﬁ  nding, it would not be an incorrect conclusion to 
suggest that the therapy duration for CsA in KCS should be 
at least six months.86Clinical Ophthalmology 2009:3 63
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Corticosteroid therapy
Corticosteroid therapy which has been used in medicine for 
many years is also preferred in many ocular diseases with 
underlying inﬂ  ammatory processes such as KCS. As was 
mentioned in the previous section, inﬂ  ammation seems to 
be a key pathogenic factor for dry eye, and because of that, 
some patients may continue to complain of eye irritation 
despite adequate aqueous enhancement therapies without any 
antiinﬂ  ammatory drugs. Numerous studies have concluded 
topical or systemic corticosteroid therapy may have several 
beneﬁ  ts in the treatment of moderate to severe dry eyes.59,87,88 
For instance, in one study reviewing the efﬁ  cacy and side 
effects of topical nonpreserved corticosteroid therapy for 
treatment of severe KCS with SS, topical nonpreserved meth-
ylprednisolone was found to be effective for severe KCS. 
However, it has been also emphasized that careful monitor-
ing is mandatory in these cases because of steroid-related 
complications.87 Similar results were obtained from another 
study that evaluated the prevalence of long-term recurrence 
after topical nonpreserved methylprednisolone pulse therapy 
for the treatment of KCS with SS.88 In an experimental dry 
eye model, the mechanisms of topical methylprednisolone 
and doxycycline in the treatment of inﬂ  ammation were 
described.59 According to that study, both agents reduced 
expression and activity of MMP-9, decreased levels of 
inﬂ  ammatory cytokines transcripts and reduced activation 
of MAPKs in the corneal epithelium.59
Besides topical use, application systemic use should also be 
kept in mind in rare but severe KCS cases.89 However, because 
of its serious life-threatening systemic complications, other 
systemic immunosuppressive agents including methotrexate, 
CsA, and inﬂ  iximab may be required and tried in the treatment 
of recalcitrant primary and secondary SS caused by systemic 
autoimmune conditions to improve tear production.89
Autologous and umbilical cord
serum eye drops
Recently, the use of both autologous and umbilical cord serum 
in the form of eye drops has been reported as an alternative 
treatment modality for severe ocular surface disorders in oph-
thalmic practice because of their components which include 
beneﬁ  cial growth factors (ie, epidermal growth factor), 
vitamins (ie, vitamin A), and a number of antiinﬂ  ammatory 
factors (ie, MMPs inhibitors such as TIMPs).2,90,91 Numerous 
studies have emphasized that the use of autologous92–94 and 
umbilical cord serum eye drops91,95 may provide satisfactory 
results in symptoms and objective signs of dry eye caused by 
severe SS, refractive surgery, and chronic GVHD.
Tetracycline
Despite its traditional antibiotic activity, tetracyclines have 
long been used for ocular surface inﬂ  ammatory diseases since 
a number of antiinﬂ  ammatory properties were discovered. 
As mentioned above, doxycycline, the semisynthetic tetracy-
cline, was found to reduce expression and activity of MMP-9, 
decreased levels of inﬂ  ammatory cytokines transcripts and 
reduced activation of MAPKs in the corneal epithelium in 
an experimental dry eye model.59 Similarly, another study 
by Li and colleagues also addressed that the efﬁ  cacy of 
doxycycline which may be due to its ability to suppress the 
JNK and ERK MAPK signaling activation and inﬂ  ammatory 
agents’ production, which is so critical in the formation of 
inﬂ  ammation induced by hyperosmolarity in human limbal 
epithelial cells.58 Tetracyclines have also been observed to 
suppress the steady state amounts of mRNA and protein of 
IL-β and to decrease the bioactivity of this major inﬂ  am-
matory cytokine in the corneal epithelium.96 In ophthalmic 
practice, doxycyclines have been used in dry eye especially 
induced by acne rosacea and severe blepharitis.97,98
Novel therapeutic agents
Numerous research continues to establish new therapeutic 
agents for cases with dry eye, in addition to the agents 
explained above. For instance, one of the promising agents is 
the anti-CD4 monoclonal antibody that was found to suppress 
the local activation of CD4+ T cells reducing the expansion of 
pathologic CD4+ T cells against α-fodrin in a mouse model 
of SS.99 There are also a few studies suggesting that systemic 
linoleic and gamma-linolenic acids, and omega-6 essential 
fatty acids may reduce the underlying ocular inﬂ  ammation 
and in turn improve the signs and symptoms of ocular dis-
comfort in KCS.100,101
The possible mechanisms, beneﬁ  ts and risks of the above-
mentioned agents are summarized in Table 1.
In conclusion, KCS is a multifactorial and complex dis-
order in which ocular surface, lacrimal gland, and lids are 
all involved in the pathogenesis. Taken together, all of the 
previously reviewed studies suggest that inﬂ  ammation seems 
to play a critical role in the formation of dry eye and thereby 
current and novel antiinﬂ  ammatory agents will continue to be 
an indispensable part of core treatment in addition to wetting 
with nonpreserved antifungal tears.
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Table 1 Possible mechanisms, beneﬁ  ts, and risks of antiinﬂ  ammatory agents used in the treatment of keratoconjunctivitis sicca
Drugs Possible mechanism Beneﬁ  ts Risks
Cyclosporine 
ophthalmic 
emulsion 
0.05% 
–   Mainly mediated by 
immune cells
–   Blocks the activa-
tion of JNK and p38 
signalling path-
ways during T cell 
activation 
–   Inhibits the 
phosphatase activity 
of calcineurin
–   Satisfactory results in 
patients with moderate 
to severe keratocon-
junctivitis sicca
– Twice daily use
–   Decreases the 
necessity of frequent 
use of artiﬁ  cial tears 
and corticosteroids
–   No signiﬁ  cant topical 
or systemic adverse 
safety ﬁ  ndings
– Ocular burning
–   Conjunctival hyper-
aemia, discharge, 
epiphora, eye 
pain, foreign body 
sensation, pruritus, 
stinging, and visual 
disturbance (most 
often blurring)
Corticosteroids –   Mainly mediated by 
immune cells
–   Reduce activation of 
MAPKs
–   Decrease levels 
of inﬂ  ammatory 
cytokines
–  Well known agents 
for many years
–   Powerful antiinﬂ  am-
matory effect
–   Serious local 
(glaucoma, cataract) 
and systemic 
adverse effects
Tetracycline –   Reduce MAPKs 
in the cornea 
epithelium
–   Reduce expression 
and activity of MMP9
–   Decrease levels of 
inﬂ  ammatory cytokines
–   Satisfactory results 
in patients with acne 
rosacea and severe 
blepharitis 
–   Systemic adverse 
effects
Autologous/ 
Umbilical cord 
serum eye 
drops
–   Contains beneﬁ  cial 
growth factors 
(epidermal growth 
factor), vitamins 
(vitamin A)
–   Contains a number 
of antiinﬂ  ammatory 
factors (MMPs inhibi-
tors such as TIMPs) 
–   Satisfactory results 
in various causes of 
keratoconjunctivitis 
sicca 
–   Difﬁ  culties in 
formulation and 
sterilization
– Serological problems 
Anti CD4 
monoclonal 
antibody
–   Suppress the local 
activation of CD4+ 
T cells 
–   It is a promising 
agent 
–   Since they have the 
ability to bind very 
speciﬁ  cally to their 
target receptor, it is 
possible to establish a 
therapeutic strategy 
with fewer side effects 
–   Further 
investigations are 
needed to clarify its 
efﬁ  cacy and safety 
in the treatment of 
dry eye 
Systemic 
linoleic, 
gamma-
linolenic acids, 
omega-6 
essential fatty 
acids
–   Has antiinﬂ  ammatory 
effects
–  Acts directly on 
T lymphocytes
–   Reduces the expres-
sion of the inﬂ  amma-
tory marker HLA-DR 
in conjunctival cells of 
subjects with dry eye
–   Increases the PGE1 
levels in tears of 
patients with SS
–   Could be of help 
in controlling the 
evolution of signs and 
symptoms of dry eye
–   Can be used with 
other antiinﬂ  amma-
tory agents with lower 
dosages thus reducing 
the risks of the ocular 
and systemic adverse 
effects of antiinﬂ  am-
matory agents.
–   Further investiga-
tions are needed to 
clarify its efﬁ  cacy 
and safety in the 
treatment of dry eye
Abbreviations: MMP, matrix metalloproteinase; JNK, c-Jun NH2 terminal kinase; MAPKs, mitogen activated protein kinases;   TIMP, tissue inhibitor of metalloproteinases; PGE1, 
prostaglandin E1.Clinical Ophthalmology 2009:3 65
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